RxDoctor Payments Data

Alexander Hou, MD

Vascular Surgery · Edgewood, KYNPI 1396820809

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $18,486 of the $22,393 with a category attached, or 82.6%. It is spread thinly across 43 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $6,886, 3.1 times the $2,196 reported in 2019.

$22,393in general payments, 2019–2025

Across 292 payments — averaging $76.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$5K
  • Inari Medical, Inc.$3K
  • Silk Road Medical, Inc.$3K
  • W. L. Gore & Associates, Inc.$2K
  • Stryker$2K
  • Johnson & Johnson$838
  • plus $6K from 37 others
$82,177in research payments, 2019–2025

Across 39 payments — averaging $2107.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inari Medical, Inc.$57K
  • Stryker$25K

What the payments were for

  • Travel & lodging$3,90717%
  • Food & beverage$18,48683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,393 in reported general payments places this provider in the 80th percentile of 72 vascular surgery providers in Kentucky.

See all vascular surgery providers in Kentucky

Medicare billing

Part B allowed, 2024
$153,130
Medicare patients
698
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$51,435
XareltoRivaroxaban46$46,869
ClopidogrelClopidogrel Bisulfate300$2,247
Cilostazol30$555
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen41$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$51,43560 claims
Johnson & JohnsonXarelto$838$46,86946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 72 vascular surgery providers in Kentucky.

Other vascular surgery in Edgewood

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →